289 | MULTICENTER REAL‐WORLD OUTCOMES OF FRONTLINE POLA‐R‐CHP IN TREATMENT NAÏVE DLBCLAlex F. Herrera, Jessica Chicola, José María Manzano et al.|Hematological Oncology|2025Cited by 2
243 | REAL‐WORLD OUTCOMES OF CD20xCD3 BISPECIFIC ANTIBODY THERAPY IN ADULT PATIENTS WITH RELAPSED/REFRACTORY TRANSFORMED INDOLENT LYMPHOMAP. Stéphan, Alexey V. Danilov, Karan Chohan et al.|Hematological Oncology|2025Cited by 1
Real-world outcomes of frontline polatuzumab-rchp and impact of frailty in older adults with diffuse large B-cell lymphomaVarun Iyengar, Pallawi Torka, Jomel Meeko Manzano et al.|Blood|2025Cited by 1
ABCL-817: Real-World Outcomes of Frontline Polatuzumab and Impact of Frailty in Older Adults With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): A Multicenter StudyJessica Chicola, Pallawi Torka, Jomel Meeko Manzano et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0
Real world outcomes of sequencing bispecific antibodies (BsAb) in patients with relapsed / refractory follicular lymphoma (R/R FL): A multi-center cohort study from cubic consortiumChijioke Nze, Narendranath Epperla, Allison M. Bock et al.|Blood|2025Cited by 0